Immunomedics Inc (IMMU) 2.48 $IMMU
IMMUNOMEDICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Immunomedics Inc. - IMMU
PR Newswire - Fri Jul 08, 9:07PM CDT
Kahn Swick & Foti, LLC ("KSF"
and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 8, 2016 to file lead plaintiff applications in a securities class action lawsuit against Immunomedics Inc. (NasdaqGM: IMMU), if they purchased the Company's securities between April 20, 2016 and June 2, 2016, inclusive (the "Class Period". This action is pending in the United States District Court for the District of New Jersey.
IMMU: 2.48 (+0.11)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Immunomedics, Inc. of Class Action Lawsuit and Upcoming Deadline - IMMU
ACCESSWIRE - Fri Jul 08, 2:20PM CDT
NEW YORK, NY / ACCESSWIRE / July 8, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against Immunomedics, Inc. ("Immunomedics" or the "Company" (NASDAQ: IMMU) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Immunomedics securities between April 20, 2016 and June 2, 2016 inclusive (the "Class Period". This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act".
IMMU: 2.48 (+0.11)
IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Immunomedics Inc. And Reminds Investors With Losses To Contact The Firm
ACCESSWIRE - Thu Jul 07, 7:55PM CDT
LOS ANGELES, CA / ACCESSWIRE / July 7, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Immunomedics Inc. ("Immunomedics" or the "Company" (Nasdaq: IMMU) concerning possible violations of federal securities laws between April 20, 2016 and June 3, 2016 (the "Class Period". Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 8, 2016 lead plaintiff motion deadline.
IMMU: 2.48 (+0.11)
Hagens Berman Reminds Immunomedics, Inc. (NASDAQ: IMMU) Investors of August 8, 2016 Lead Plaintiff Deadline in Securities Class Action
GlobeNewswire - Tue Jul 05, 7:30AM CDT
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, reminds Immunomedics, Inc. (NASDAQ:IMMU) investors of the August 8, 2016 Lead Plaintiff deadline in the securities class action filed in the United States District Court for the District of New Jersey.
IMMU: 2.48 (+0.11)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunomedics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 8, 2016 - IMMU
GlobeNewswire - Fri Jul 01, 9:11AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
IMMU: 2.48 (+0.11)
Why Investors Love These Biotech's Stocks? - ImmunoGen, Immunomedics, Vanda Pharma, and Arrowhead Pharma
PR Newswire - Thu Jun 30, 7:45AM CDT
Lagging the market yesterday was the Biotech space, which continues to be challenged by costs, economic uncertainty, and policies. Stock-Callers.com reviews the recent performances of the following equities today: ImmunoGen Inc. (NASDAQ: IMGN), Immunomedics Inc. (NASDAQ: IMMU), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR). Sign up for your complimentary trade alerts on these stocks at:
IMMU: 2.48 (+0.11), ARWR: 5.73 (+0.17), VNDA: 11.47 (+0.02), IMGN: 3.20 (+0.08)
SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Immunomedics Inc. and Reminds Investors with Losses to Contact the Firm
BusinessWire - Wed Jun 29, 10:51AM CDT
Khang & Khang LLP (the "Firm" announces that a class action lawsuit has been filed against Immunomedics Inc. ("Immunomedics" or the "Company" (Nasdaq: IMMU). Investors who purchased or otherwise acquired shares between April 20, 2016 and June 2, 2016 inclusive (the "Class Period", are encouraged to contact the Firm prior to the August 8, 2016, lead plaintiff motion deadline.
IMMU: 2.48 (+0.11)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Immunomedics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit - IMMU
GlobeNewswire - Tue Jun 28, 9:00PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Immunomedics, Inc. (Nasdaq:IMMU) ("Immunomedics" or the "Company" securities during the period between April 20, 2016 and June 3, 2016, inclusive (the "Class Period". Investors with losses in excess of $100,000 who wish to become proactively involved in the litigation have until August 8, 2016 to seek appointment as lead plaintiff.
IMMU: 2.48 (+0.11)
Immunomedics Announces New U.S. Patent for Sacituzumab Govitecan (Immu-132) Antibody-Drug Conjugate (ADC)
GlobeNewswire - Tue Jun 28, 6:00AM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today announced the issuance of U.S. Patent 9,375,489, entitled "Antibody-SN-38 Immunoconjugates with a CL2A Linker." This is the 28 issued U.S. patent covering the composition and uses of sacituzumab govitecan (IMMU-132), the Company's lead cancer therapeutic. Sacituzumab govitecan is an antibody-drug conjugate (ADC) comprising a humanized antibody to the cancer marker, Trop-2, conjugated with SN-38, the active metabolite of the well-known anticancer drug, irinotecan. This ADC is in development for the treatment of patients with many diverse solid cancers, with initial results reported at various meetings and in Clinical Cancer Research.The most advanced indication in development is triple-negative breast cancer (TNBC), with Phase 2 studies also continuing in patients with metastatic non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), and in patients with metastatic urothelial cancers.
IMMU: 2.48 (+0.11)
DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit Against Immunomedics Inc. And Reminds Investors With Losses To Contact The Firm
ACCESSWIRE - Mon Jun 27, 4:31PM CDT
LOS ANGELES, CA / ACCESSWIRE / June 27, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Immunomedics Inc. ("Immunomedics" or the "Company" (Nasdaq: IMMU) concerning possible violations of federal securities laws between April 20, 2016 and June 3, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 8, 2016, lead plaintiff motion deadline.
IMMU: 2.48 (+0.11)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunomedics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 8, 2016 - IMMU
ACCESSWIRE - Mon Jun 27, 9:21AM CDT
NEW YORK, NY / ACCESSWIRE / June 27, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
IMMU: 2.48 (+0.11)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of a Class Action against Immunomedics Inc. (IMMU) and Lead Platintiff Deadline: August 8, 2016
ACCESSWIRE - Mon Jun 27, 9:19AM CDT
NEW YORK, NY / ACCESSWIRE / June 27, 2016 / Bronstein, Gewirtz & Grossman, LLC, notifies investors of a class action against Immunomedics, Inc. ("Immunomedics" or the "Company" (NASDAQ-GM: IMMU). The class action has been filed in the United States District Court, District of New Jersey, on behalf of a class consisting of all persons or entities who purchased Immunomedics common stock between April 20, 2016 and June 2, 2016 inclusive (the "Class Period".
IMMU: 2.48 (+0.11)
SHAREHOLDER ALERT: Rosen Law Firm Reminds Immunomedics, Inc. Investors of Important Deadline in Class Action - IMMU
BusinessWire - Thu Jun 23, 2:34PM CDT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Immunomedics, Inc. securities (NASDAQ:IMMU) from April 20, 2016 through June 2, 2016, both dates inclusive (the "Class Period" of the important August 8, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Immunomedics investors under the federal securities laws.
IMMU: 2.48 (+0.11)
DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Immunomedics Inc. and Reminds Investors with Losses to Contact the Firm
BusinessWire - Thu Jun 23, 4:30AM CDT
Lundin Law PC announces a class action lawsuit has been filed against Immunomedics Inc. ("Immunomedics" or the "Company" (Nasdaq: IMMU) concerning possible violations of federal securities laws between April 20, 2016 and June 3, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 8, 2016, lead plaintiff motion deadline.
IMMU: 2.48 (+0.11)
IMMUNOMEDICS, INC. INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
BusinessWire - Mon Jun 20, 4:52PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Immunomedics, Inc. (Nasdaq: IMMU) ("Immunomedics" or the "Company" securities during the period between April 20, 2016 and June 3, 2016, inclusive (the "Class Period". Investors with losses in excess of $100,000 who wish to become proactively involved in the litigation have until August 8, 2016 to seek appointment as lead plaintiff.
IMMU: 2.48 (+0.11)
INVESTOR NOTICE: Lundin Law PC Announces Investigation Of Immunomedics Inc. And Advises Investors With Losses to Contact the Firm
BusinessWire - Mon Jun 20, 11:12AM CDT
Lundin Law PC announces it is investigating claims against Immunomedics Inc. ("Immunomedics" or the "Company" (Nasdaq: IMMU) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Immunomedics were false and misleading and/or failed to disclose material information regarding the Company's financial performance.
IMMU: 2.48 (+0.11)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunomedics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 8, 2016 -- IMMU
Marketwired - Mon Jun 20, 10:05AM CDT
NEW YORK, NY--(Marketwired - June 20, 2016) - The following statement is being issued by Levi & Korsinsky, LLP:
IMMU: 2.48 (+0.11)
IMMUNOMEDICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Immunomedics Inc.
BusinessWire - Fri Jun 17, 9:07PM CDT
Kahn Swick & Foti, LLC ("KSF" and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 8, 2016 to file lead plaintiff applications in a securities class action lawsuit against Immunomedics Inc. (NasdaqGM: IMMU), if they purchased the Company's securities between April 20, 2016 and June 2, 2016, inclusive (the "Class Period". This action is pending in the United States District Court for the District of New Jersey.
IMMU: 2.48 (+0.11)
IMMUNOMEDICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Immunomedics Inc. - IMMU
PR Newswire - Fri Jul 08, 9:07PM CDT
Kahn Swick & Foti, LLC ("KSF"
and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 8, 2016 to file lead plaintiff applications in a securities class action lawsuit against Immunomedics Inc. (NasdaqGM: IMMU), if they purchased the Company's securities between April 20, 2016 and June 2, 2016, inclusive (the "Class Period". This action is pending in the United States District Court for the District of New Jersey. IMMU: 2.48 (+0.11)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Immunomedics, Inc. of Class Action Lawsuit and Upcoming Deadline - IMMU
ACCESSWIRE - Fri Jul 08, 2:20PM CDT
NEW YORK, NY / ACCESSWIRE / July 8, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against Immunomedics, Inc. ("Immunomedics" or the "Company"
(NASDAQ: IMMU) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Immunomedics securities between April 20, 2016 and June 2, 2016 inclusive (the "Class Period". This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act". IMMU: 2.48 (+0.11)
IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Immunomedics Inc. And Reminds Investors With Losses To Contact The Firm
ACCESSWIRE - Thu Jul 07, 7:55PM CDT
LOS ANGELES, CA / ACCESSWIRE / July 7, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Immunomedics Inc. ("Immunomedics" or the "Company"
(Nasdaq: IMMU) concerning possible violations of federal securities laws between April 20, 2016 and June 3, 2016 (the "Class Period". Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 8, 2016 lead plaintiff motion deadline. IMMU: 2.48 (+0.11)
Hagens Berman Reminds Immunomedics, Inc. (NASDAQ: IMMU) Investors of August 8, 2016 Lead Plaintiff Deadline in Securities Class Action
GlobeNewswire - Tue Jul 05, 7:30AM CDT
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, reminds Immunomedics, Inc. (NASDAQ:IMMU) investors of the August 8, 2016 Lead Plaintiff deadline in the securities class action filed in the United States District Court for the District of New Jersey.
IMMU: 2.48 (+0.11)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunomedics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 8, 2016 - IMMU
GlobeNewswire - Fri Jul 01, 9:11AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
IMMU: 2.48 (+0.11)
Why Investors Love These Biotech's Stocks? - ImmunoGen, Immunomedics, Vanda Pharma, and Arrowhead Pharma
PR Newswire - Thu Jun 30, 7:45AM CDT
Lagging the market yesterday was the Biotech space, which continues to be challenged by costs, economic uncertainty, and policies. Stock-Callers.com reviews the recent performances of the following equities today: ImmunoGen Inc. (NASDAQ: IMGN), Immunomedics Inc. (NASDAQ: IMMU), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR). Sign up for your complimentary trade alerts on these stocks at:
IMMU: 2.48 (+0.11), ARWR: 5.73 (+0.17), VNDA: 11.47 (+0.02), IMGN: 3.20 (+0.08)
SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Immunomedics Inc. and Reminds Investors with Losses to Contact the Firm
BusinessWire - Wed Jun 29, 10:51AM CDT
Khang & Khang LLP (the "Firm"
announces that a class action lawsuit has been filed against Immunomedics Inc. ("Immunomedics" or the "Company" (Nasdaq: IMMU). Investors who purchased or otherwise acquired shares between April 20, 2016 and June 2, 2016 inclusive (the "Class Period", are encouraged to contact the Firm prior to the August 8, 2016, lead plaintiff motion deadline. IMMU: 2.48 (+0.11)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Immunomedics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit - IMMU
GlobeNewswire - Tue Jun 28, 9:00PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Immunomedics, Inc. (Nasdaq:IMMU) ("Immunomedics" or the "Company"
securities during the period between April 20, 2016 and June 3, 2016, inclusive (the "Class Period". Investors with losses in excess of $100,000 who wish to become proactively involved in the litigation have until August 8, 2016 to seek appointment as lead plaintiff. IMMU: 2.48 (+0.11)
Immunomedics Announces New U.S. Patent for Sacituzumab Govitecan (Immu-132) Antibody-Drug Conjugate (ADC)
GlobeNewswire - Tue Jun 28, 6:00AM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today announced the issuance of U.S. Patent 9,375,489, entitled "Antibody-SN-38 Immunoconjugates with a CL2A Linker." This is the 28 issued U.S. patent covering the composition and uses of sacituzumab govitecan (IMMU-132), the Company's lead cancer therapeutic. Sacituzumab govitecan is an antibody-drug conjugate (ADC) comprising a humanized antibody to the cancer marker, Trop-2, conjugated with SN-38, the active metabolite of the well-known anticancer drug, irinotecan. This ADC is in development for the treatment of patients with many diverse solid cancers, with initial results reported at various meetings and in Clinical Cancer Research.The most advanced indication in development is triple-negative breast cancer (TNBC), with Phase 2 studies also continuing in patients with metastatic non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), and in patients with metastatic urothelial cancers.
IMMU: 2.48 (+0.11)
DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit Against Immunomedics Inc. And Reminds Investors With Losses To Contact The Firm
ACCESSWIRE - Mon Jun 27, 4:31PM CDT
LOS ANGELES, CA / ACCESSWIRE / June 27, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Immunomedics Inc. ("Immunomedics" or the "Company"
(Nasdaq: IMMU) concerning possible violations of federal securities laws between April 20, 2016 and June 3, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 8, 2016, lead plaintiff motion deadline. IMMU: 2.48 (+0.11)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunomedics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 8, 2016 - IMMU
ACCESSWIRE - Mon Jun 27, 9:21AM CDT
NEW YORK, NY / ACCESSWIRE / June 27, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
IMMU: 2.48 (+0.11)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of a Class Action against Immunomedics Inc. (IMMU) and Lead Platintiff Deadline: August 8, 2016
ACCESSWIRE - Mon Jun 27, 9:19AM CDT
NEW YORK, NY / ACCESSWIRE / June 27, 2016 / Bronstein, Gewirtz & Grossman, LLC, notifies investors of a class action against Immunomedics, Inc. ("Immunomedics" or the "Company"
(NASDAQ-GM: IMMU). The class action has been filed in the United States District Court, District of New Jersey, on behalf of a class consisting of all persons or entities who purchased Immunomedics common stock between April 20, 2016 and June 2, 2016 inclusive (the "Class Period". IMMU: 2.48 (+0.11)
SHAREHOLDER ALERT: Rosen Law Firm Reminds Immunomedics, Inc. Investors of Important Deadline in Class Action - IMMU
BusinessWire - Thu Jun 23, 2:34PM CDT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Immunomedics, Inc. securities (NASDAQ:IMMU) from April 20, 2016 through June 2, 2016, both dates inclusive (the "Class Period"
of the important August 8, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Immunomedics investors under the federal securities laws. IMMU: 2.48 (+0.11)
DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Immunomedics Inc. and Reminds Investors with Losses to Contact the Firm
BusinessWire - Thu Jun 23, 4:30AM CDT
Lundin Law PC announces a class action lawsuit has been filed against Immunomedics Inc. ("Immunomedics" or the "Company"
(Nasdaq: IMMU) concerning possible violations of federal securities laws between April 20, 2016 and June 3, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 8, 2016, lead plaintiff motion deadline. IMMU: 2.48 (+0.11)
IMMUNOMEDICS, INC. INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
BusinessWire - Mon Jun 20, 4:52PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Immunomedics, Inc. (Nasdaq: IMMU) ("Immunomedics" or the "Company"
securities during the period between April 20, 2016 and June 3, 2016, inclusive (the "Class Period". Investors with losses in excess of $100,000 who wish to become proactively involved in the litigation have until August 8, 2016 to seek appointment as lead plaintiff. IMMU: 2.48 (+0.11)
INVESTOR NOTICE: Lundin Law PC Announces Investigation Of Immunomedics Inc. And Advises Investors With Losses to Contact the Firm
BusinessWire - Mon Jun 20, 11:12AM CDT
Lundin Law PC announces it is investigating claims against Immunomedics Inc. ("Immunomedics" or the "Company"
(Nasdaq: IMMU) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Immunomedics were false and misleading and/or failed to disclose material information regarding the Company's financial performance. IMMU: 2.48 (+0.11)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunomedics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 8, 2016 -- IMMU
Marketwired - Mon Jun 20, 10:05AM CDT
NEW YORK, NY--(Marketwired - June 20, 2016) - The following statement is being issued by Levi & Korsinsky, LLP:
IMMU: 2.48 (+0.11)
IMMUNOMEDICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Immunomedics Inc.
BusinessWire - Fri Jun 17, 9:07PM CDT
Kahn Swick & Foti, LLC ("KSF"
and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 8, 2016 to file lead plaintiff applications in a securities class action lawsuit against Immunomedics Inc. (NasdaqGM: IMMU), if they purchased the Company's securities between April 20, 2016 and June 2, 2016, inclusive (the "Class Period". This action is pending in the United States District Court for the District of New Jersey. IMMU: 2.48 (+0.11)
